Scientific publications

Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies

Martinez-Valbuena I (1,2,3), Amat-Villegas I (3,4), Valenti-Azcarate R (1,2,3), Carmona-Abellan MDM (1,2,3), Marcilla I (2,3), Tuñon MT (3,4), Luquin MR (5,6,7).

(1) Neurology Department, Clinica Universidad de Navarra, Avenida de Pio XII 36, 31008, Pamplona, Navarra, Spain.
(2) Regenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(3) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
(4) Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
(5) Neurology Department, Clinica Universidad de Navarra, Avenida de Pio XII 36, 31008, Pamplona, Navarra, Spain.
(6) Regenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(7) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.

Magazine: Acta Neuropathologica

Date: Mar 13, 2018

Neurology [SP]

RESUMO

Parkinson's disease patients experience a wide range of non-motor symptoms that may be provoked by deposits of phosphorylated α-synuclein in the peripheral nervous system.

Pre-existing diabetes mellitus might be a risk factor for developing Parkinson's disease, and indeed, nearly 60% of Parkinson's disease patients are insulin resistant. Thus, we have investigated whether phosphorylated α-synuclein is deposited in pancreatic tissue of subjects with synucleinopathies.

We studied pancreatic tissue from 39 subjects diagnosed with Parkinson's disease, Lewy body Dementia or incidental Lewy bodies disease, as well as that from 34 subjects with diabetes mellitus and a normal neuropathological examination, and 52 subjects with a normal neuropathological examination.

We examined the pancreatic accumulation of phosphorylated α-synuclein and of the islet amyloid polypeptide precursor (IAPP), an amyloidogenic protein that plays an unknown role in diabetes mellitus, but that can promote α-synuclein amyloid deposition in vitro.

Moreover, we performed proximity ligation assays to assess whether these two proteins interact in the pancreas of these subjects. Cytoplasmic phosphorylated α-synuclein deposits were found in the pancreatic β cells of 14 subjects with Parkinson's disease (93%), in 11 subjects with Lewy body Dementia (85%) and in 8 subjects with incidental Lewy body disease (73%).

Furthermore, we found similar phosphorylated α-synuclein inclusions in 23 subjects with a normal neuropathological examination but with diabetes mellitus (68%) and in 9 control subjects (17%). In addition, IAPP/α-synuclein interactions appear to occur in patients with pancreatic inclusions of phosphorylated α-synuclein.

The presence of phosphorylated α-synuclein inclusions in pancreatic β cells provides a new evidence of a mechanism that is potentially common to the pathogenesis of diabetes mellitus, PD and DLB.

Moreover, the interaction of IAPP and α-synuclein in the pancreatic β cells of patients may represent a novel target for the development of strategies to treat these diseases.

CITATION  Acta Neuropathol. 2018 Mar 13. doi: 10.1007/s00401-018-1832-0

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra